When a patient is diagnosed with Type 2 diabetes, physicians rarely think of chronic pancreatitis as the cause. But about 50% of people diagnosed with chronic pancreatitis will develop diabetes. Three national, multicenter studies led by Cedars-Sinai investigators are now exploring the connections between diabetes and chronic pancreatitis and pancreatic cancer.

DETECT focuses on the lesser-known, often misdiagnosed Type 3c diabetes. The study’s main goal “is to develop a diagnostic test that can distinguish diabetes caused by pancreatitis or pancreatic cancer from the more common Type 2 diabetes,” says Mark Goodarzi, MD, PhD, director of Endocrinology, Diabetes and Metabolism, and the Eris M. Field Chair in Diabetes Research. 

New-Onset Diabetes (NOD) aims to reduce the death rate from the most common form of pancreatic cancer: pancreatic ductal adenocarcinoma. The study will focus on identifying biomarkers for early detection of pancreatic cancer.

PROCEED seeks to provide reliable estimates about progression of chronic pancreatitis and also test the predictive capability of numerous biomarkers.